Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

11.29 +0.06 (+0.53%)
Streaming Delayed Price Updated: 10:55 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Omeros Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
From Omeros Corporation
Via Business Wire
North America Could Possibly Emerge as the Market Leader for Billion Dollar Detox Drinks Industry
EQNX::TICKER_START (NASDAQ:CELH),(NASDAQ:OMER),(NYSE:MRK),(NASDAQ:RXDX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Third Quarter 2022 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
From Omeros Corporation
Via Business Wire
News headline image
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19
From Quantum Leap Healthcare Collaborative and Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation Reports Second Quarter 2022 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
From Omeros Corporation
Via Business Wire
News headline image
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Webcast Details for Annual Meeting of Shareholders
From Omeros Corporation
Via Business Wire
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
Via AB Newswire
News headline image
Omeros Corporation Reports First Quarter 2022 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
From Omeros Corporation
Via Business Wire
News headline image
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
From Omeros Corporation
Via Business Wire
News headline image
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
News headline image
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation (NASDAQ:OMER) Investor Notice: Investigation over Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 12/14/2021 -- Certain directors of Omeros Corporation are under investigation over potential breaches of fiduciary duties. 
Via SBWire
News headline image
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
From Omeros Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.